Neumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 3,760 put options on the company. This represents an increase of approximately 47% compared to the typical volume of 2,556 put options.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA traded up $0.27 during midday trading on Monday, hitting $11.12. 959,783 shares of the company's stock traded hands, compared to its average volume of 750,894. The firm has a fifty day moving average of $11.61 and a 200 day moving average of $11.55. Neumora Therapeutics has a 1 year low of $8.33 and a 1 year high of $21.00. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -5.95 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same quarter last year, the firm earned ($1.14) EPS. On average, equities analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Insider Buying and Selling at Neumora Therapeutics

In related news, insider Robert A. Lenz sold 5,563 shares of the company's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the transaction, the insider now directly owns 322,966 shares of the company's stock, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares in the company, valued at approximately $342,303. This represents a 41.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank raised its stake in Neumora Therapeutics by 472.8% during the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after acquiring an additional 2,402 shares during the period. Quarry LP purchased a new position in shares of Neumora Therapeutics during the 2nd quarter valued at $98,000. SkyOak Wealth LLC purchased a new position in shares of Neumora Therapeutics during the 2nd quarter valued at $147,000. Principal Financial Group Inc. bought a new position in Neumora Therapeutics in the 2nd quarter worth $166,000. Finally, Intech Investment Management LLC purchased a new stake in Neumora Therapeutics in the 3rd quarter worth $175,000. 47.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NMRA. Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada restated an "outperform" rating and set a $29.00 target price on shares of Neumora Therapeutics in a research note on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Monday, December 16th. Finally, JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Neumora Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $23.40.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.